Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

To investigate the role of the dopamine transporter (DAT) in the regulation of synaptic dopamine (DA) levels in Parkinson's disease and its role in the preservation of DA in presynaptic terminals.

[1]  T. Aigner,et al.  New rapid analysis method demonstrates differences in 6-[18F] fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[2]  R. Albin,et al.  Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of l-DOPA and pramipexole , 2003, Experimental Neurology.

[3]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[4]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[5]  V. Sossi,et al.  DTBZ-PET correlates of levodopa responses in asymmetric Parkinson ' s disease , 2003 .

[6]  G. Uhl,et al.  Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. , 1999, Brain research. Molecular brain research.

[7]  T. Chase,et al.  Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates , 2005, Experimental Neurology.

[8]  V. Sossi,et al.  Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.

[9]  J. Holden,et al.  6‐[18F]fluoro‐L‐DOPA PET studies of the turnover of dopamine in MPTP‐induced parkinsonism in monkeys , 1998, Synapse.

[10]  Vesna Sossi,et al.  Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.

[11]  N. Volkow,et al.  Dopamine transporters decrease with age. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Farrer,et al.  Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.

[13]  M Slifstein,et al.  Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Nutt,et al.  The dopamine transporter: Importance in Parkinson's disease , 2004, Annals of neurology.

[15]  Fabrizio Stocchi,et al.  Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. , 2005, Archives of neurology.

[16]  Yen F. Tai,et al.  Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.

[17]  D. Calne,et al.  Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. , 2004, Brain : a journal of neurology.

[18]  E. Hirsch.  Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. , 2000, Annals of neurology.

[19]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  V Sossi,et al.  A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[22]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[23]  T. Chase,et al.  Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD , 2005, Experimental Neurology.

[24]  V. Sossi,et al.  Quantitative comparison of three- and two-dimensional PET with human brain studies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[26]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[27]  V. Sossi,et al.  Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[29]  T J Spinks,et al.  Physical performance of a positron tomograph for brain imaging with retractable septa. , 1992, Physics in medicine and biology.

[30]  A. Rajput,et al.  Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.

[31]  R. Gainetdinov,et al.  Dopamine Transporter Is Required for In Vivo MPTP Neurotoxicity: Evidence from Mice Lacking the Transporter , 1997, Journal of neurochemistry.

[32]  M. Bannon.  The dopamine transporter: role in neurotoxicity and human disease. , 2005, Toxicology and applied pharmacology.

[33]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[34]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[35]  R. Hen,et al.  Hyperactivity and impaired response habituation in hyperdopaminergic mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  V. Sossi,et al.  [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. , 2003, Brain : a journal of neurology.